


## Sample case

### Invasive ductal breast carcinoma



Clinical History	
Prior	6 lines of therapy, including trastuzumab
	Tissue and blood analysis by DCGL: PIK3CA driver mutation H1047R detected in tissue and blood
Feb '18	Recommendation of lapatinib in combination with everolimus (though hormone receptor negative)
Mar '18	Use of cfDNA and CTC for disease monitoring (cancertrack)
May '18	Decrease in MAF of PIK3CA and CTC count along with response seen on PET-CT

Both ctDNA and CTCs proved to be clinically relevant sources of information in this case. A therapy-relevant mutation was detected not only in the tumour tissue, but also in the blood. The positive course of therapy was consistently reflected in the dynamics of both markers – ctDNA and CTCs. cancertrack monitoring is therefore a multifunctional and practical tool in cancer therapy.

### Relapse

January 2018

### Follow-up

May 2018

#### Contact us:

☎ +49 (0)160 91588059  
 ☎ +49 (0)921 50739395  
 ✉ info-eu@datargpx.com  
 🌐 datargpx.de

**DATAR CANCER  
GENETICS - EUROPE**  
GmbH

**DATAR CANCER GENETICS**  
 UNITED KINGDOM | GERMANY | INDIA

